High-level Skp2 Expression in Pancreatic Ductal Adenocarcinoma

Einama, Takahiro; Kagata, Yutaka; Tsuda, Hitoshi; Morita, Daisaku; Ogata, Sho; Ueda, Shigeto; Takigawa, Toshimichi; Kawarabayashi, Nobuaki; Fukatsu, Kazuhiko; Sugiura, Yoshimi; Matsubara, Osamu; Hatsuse, Kazuo

doi:10.1097/01.mpa.0000220862.78248.c4

Cited by 34 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher expression of Skp2 is associated with poor prognosis in human cancers including pancreatic cancer,58,59 prostate cancer,59 breast cancer,60,61 and glioma 62. Wang et al reported that Skp2 expression predicted poor prognosis and maintained the cancer stem cell pool in NPC 63–65.…”

Section: Discussionmentioning

confidence: 99%

Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells

Feng¹,

Wang²,

Zhang³

et al. 2017

OTT

View full text Add to dashboard Cite

Curcumin, a natural polyphenol compound, exhibits tumor suppressive activity in a wide spectrum of cancers, including nasopharyngeal carcinoma cells. However, the exact molecular mechanisms governing this tumor suppressive activity remain elusive. Multiple studies have revealed that miRNAs are critically involved in tumorigenesis, indicating that targeting miRNAs could be a therapeutic strategy for treating human cancer. In the current study, we set out to determine whether curcumin regulates miR-7 expression in nasopharyngeal carcinoma cells. We found that curcumin inhibited cell growth, induced apoptosis, retarded cell migration and invasion, and triggered cell cycle arrest in the human nasopharyngeal carcinoma cell lines CNE1 and CNE2. Importantly, we observed that curcumin upregulated the expression of miR-7 and subsequently inhibited Skp2, a direct miR-7 target. Our results identified that upregulation of miR-7 by curcumin could benefit nasopharyngeal carcinoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells

Feng¹,

Wang²,

Zhang³

et al. 2017

OTT

View full text Add to dashboard Cite

show abstract

“…Recently, molecular biomarkers such as RhoA expression, LMO2 expression, or Skp2 expression have also been suggested as novel predictive markers for pancreatic carcinoma [21,22,23]. We have reported that the KRAS mutation predicts poor survival in patients with pancreatic cancer [24].…”

Section: Discussionmentioning

confidence: 99%

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

Lee

Park

et al. 2011

Oncology

View full text Add to dashboard Cite

Objective: Our aim was to devise a prognostic model for advanced pancreatic cancer based on clinical parameters. Methods: We retrospectively analyzed the medical records of 298 patients who received gemcitabine-based chemotherapy from January 1999 to November 2008. Results: The median survival of all patients was 7 months [95% confidence interval (CI) 6.2–7.8]. Multivariate analysis revealed poor prognostic factors for overall survival such as the presence of liver metastasis [p < 0.001, hazard ratio (HR) 2.628, 95% CI 1.620–4.264], the presence of ascites or peritoneal carcinomatosis (p = 0.005, HR 1.783, 95% CI 1.194–2.661), serum C-reactive protein levels >1.2 mg/dl (p = 0.021, HR 1.568, 95% CI 1.070–2.300), and serum albumin levels <3.5 g/dl (p = 0.021, HR 1.701, 95% CI 1.085–2.667). Of 298 patients, 168 patients (56.4%) were categorized as low-risk with 0 or 1 risk factor, 80 patients (26.8%) were categorized as intermediate-risk with 2 risk factors, and 50 patients (16.8%) were categorized as high-risk with 3 or 4 risk factors. The median survival duration for the low-, intermediate-, and high-risk groups was 10.0 months (95% CI 8.7–11.3), 6.7 months (95% CI 5.7–7.7), and 4.4 months (95% CI 3.2–5.6), respectively. Conclusions: This prognostic model could help to select treatment for patients in clinical practice, and these risk-adapted treatment strategies should be further investigated in prospective studies in such patient populations.

show abstract

“…Recently, it has been reported that Skp2 expression correlated significantly with histological grade and tumor size in human hepatocellular carcinoma [44]. Moreover, a correlation between elevated Skp2 protein expression and tumor metastasis has been noted in multiple tumors, including melanoma [35], oral squamous cell carcinomas [45], pancreatic cancer [46], and breast carcinoma [47]. Furthermore, Skp2 expression has been discovered to predict for poor prognosis in breast cancer [47], melanoma [35], and nasopharyngeal carcinoma [36].…”

Section: Skp2 Is a Bona Fide Proto-oncoproteinmentioning

confidence: 99%

Skp2: A novel potential therapeutic target for prostate cancer

Wang

Gao

Fukushima

et al. 2012

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

115

View full text Add to dashboard Cite

Prostate cancer is the most frequently diagnosed tumor in men and the second most common cause of cancer-related death for males in the United States. It has been shown that multiple signaling pathways are involved in the pathogenesis of prostate cancer, such as androgen receptor (AR), Akt, Wnt, Hedgehog (Hh) and Notch. Recently, burgeoning amounts of evidence have implicated that the F-box protein Skp2 (S-phase kinase associated protein 2), a well-characterized oncoprotein, also plays a critical role in the development and progression of prostate cancer. Therefore, this review discusses the recent literature regarding the function and regulation of Skp2 in the pathogenesis of prostate cancer. Furthermore, we highlight that Skp2 may represent an attractive therapeutic target, thus warrants further development of agents to target Skp2, which could have significant therapeutic impact on prostate cancer.

show abstract

High-level Skp2 Expression in Pancreatic Ductal Adenocarcinoma

Abstract: It is suggested that examination of Skp2 expression might be clinically useful for prognostication in patients with pancreatic carcinoma and that Skp2 protein might be a novel therapeutic molecular target.

Cited by 34 publications

References 27 publications

Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells

Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

Skp2: A novel potential therapeutic target for prostate cancer

Contact Info

Product

Resources

About